Treatment of mcrpc in patients. Medical search. Frequent questions

In fact, that is the study that led to rucaparib being approved by the FDA for the treatment of prostate cancer with BRCA mutations. (curetoday.com)
The indication CHMP recommended is applicable to all patients, with or without gene mutations. (pfizer.com)
Data presented during the 2022 Genitourinary Cancers Symposium showed that compared with placebo plus abiraterone, niraparib plus abiraterone led to a 47% reduction in the risk of progression or death in patients with BRCA1 / 2 mutations and a 27% reduction in the risk of progression or death in all patients with HRR gene alterations. (urologytimes.com)
Approximately 10% of patients with mCRPC will have BRCA mutations, which are associated with a poor prognosis and worse outcomes. (yahoo.com)
The regulatory decision was based on findings from the phase 2 TRITON2 study, in which rucaparib induced a 43.9% overall response rate and a 52% confirmed prostate-specific antigen response rate in patients with mCRPC who harbored BRCA1/2 mutations. (onclive.com)
If approved the combination will be the first DAT available in the European Union for first-line treatment of adults with gene-mutated metastatic castration resistant prostate cancer (mCRPC) with BRCA1/2 (the genes that can offer protection from certain cancers) mutations. (outsourcing-pharma.com)
Results from the phase 3 Magnitude study which showed Niraparib being added to AA plus P showed a significantly improved radiographic progression-free survival compared to standard care in untreated mCRPC patients with the mutations. (outsourcing-pharma.com)
The company found that patients with mCRPC and BRCA gene mutations are more likely to have aggressive disease, poor outcomes and a shorter survival time. (outsourcing-pharma.com)
BRCA1/2 gene mutations have been identified in approximately 10-15 percent of patients with mCRPC. (outsourcing-pharma.com)
Consultant oncologist, Elena Castro, who works at Sanitaria Hospital, Madrid, said: "Metastatic castration-resistant prostate cancer remains a lethal disease, with high unmet needs in terms of treatment options, particularly for patients with BRCA1/2 gene mutations. (outsourcing-pharma.com)
In Magnitude, a total of 423 patients with HRR gene alterations were enrolled, 225 (53.2%) of whom had BRCA mutations. (outsourcing-pharma.com)
In recent years, we've focused on precision medicine in prostate cancer because we know patients with gene mutations, such as BRCA1/2, face a worse prognosis than those without," said Martin Vogel, EMEA therapeutic area lead oncology, Janssen-Cilag GmbH. (outsourcing-pharma.com)
The positive CHMP opinion reinforces the benefit of this niraparib combination and marks an important milestone in addressing BRCA1/2 mutations as we continue to drive progress towards changing the outlook for patients with mCRPC. (outsourcing-pharma.com)
The data from Magnitude supports the significant value of biomarker testing to identify the subgroup of patients most likely to derive a clinical benefit from a targeted treatment and overcome the poor prognosis of mCRPC with BRCA mutations," said Kiran Patel, vice president, clinical development, solid tumors, Janssen research & development, LLC. (outsourcing-pharma.com)
The dual biomarker of ARID1A mutations and CXCL13 expression was associated with improved overall survival in patients with advanced urothelial carcinoma. (urologytimes.com)
The product has similar indications in the United States but is also approved there for use in men with metastatic castration-resistant prostate cancer (mCRPC) that harbors deleterious BRCA mutations (germline and/or somatic). (medscape.com)
Primary and metastatic castration-resistant prostate cancers (mCRPC) have previously been shown to fall into genomic subtypes, and trials are now ongoing to test targeted treatments, such as PARP inhibitors and AKT inhibitors, in patients with particular gene mutations, the authors wrote. (genengnews.com)
Findings from the integrative analysis approach indicated that patients with mutations in the retinoblastoma (RB1) were 3.3 times more likely to die as men without RB1 alterations, and were also 7.7 times more likely to relapse on standard therapy. (genengnews.com)
Conversely, while mutations in the DNA repair genes BRCA1, BRCA2, and ATM, and in PI3K, were relatively common, they weren't linked with treatment success or overall survival. (genengnews.com)
If approved, this will be the first DAT formulation available in the U.S. to patients with mCRPC with BRCA mutations, which are a type of homologous recombination repair (HRR) gene alt. (medworm.com)
Tumor resistance mechanisms such as AR LBD mutations are increasing with earlier use of NHAs, leaving limited treatment options for men with prostate cancer in the post-NHA setting," said John Houston, Ph.D., president and chief executive officer at Arvinas. (nlvpartners.com)
It's very exciting to see ARV-766 show signs of efficacy in these late-line patients, including in patients with L702H mutations. (nlvpartners.com)
AR LBD mutations were present in 28% (13 of 47) of patients' tumors in the Phase 1/2 trial as determined by plasma DNA analysis. (nlvpartners.com)
Across the Phase 1 and interim Phase 2 data, ARV-766 achieved a 42% PSA50 in patients with AR LBD mutations. (nlvpartners.com)

The first patient has received TLX591, an antibody-based treatment for PSMA-positive metastatic castrate-resistant prostate cancer. (curetoday.com)
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, clarifies testing for the HRR mutation in metastatic castrate-resistant prostate cancer (mCRPC) and the predictive importance of radiographic progression-free survival (rPFS) for overall survival in this setting. (ajmc.com)
Radiographic progression-free survival is used really as a primary end point in most trials in first-line metastatic castrate-resistant prostate cancer because we know OS can take time to assess, can be challenging sometimes also with multiple lines of treatments, and we don't want to delay potential access to impactful medicine while waiting for OS. (ajmc.com)
SEAL BEACH, Calif.-( BUSINESS WIRE )-Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced publication of results from its PROCEED registry, which evaluated real-world use of PROVENGE ® (sipuleucel-T) in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). (gabio.org)
PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer. (gabio.org)
As a consequence, PSMA has attracted attention as a target for molecular imaging and for targeted radioligand therapy, especially in metastatic castrate-resistant prostate cancer (mCRPC). (snmjournals.org)
The Society of Nuclear Medicine and Molecular Imaging has released a consensus statement that provides standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177 Lu-PSMA radionuclide therapy. (appliedradiology.com)
Its product candidate, P-PSMA- ALLO1, is being developed for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). (investing.com)
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177Lu-PSMA radionuclide therapy. (news-medical.net)

non- BRCA subgroup OS HR=0.92 [95% CI, 0.74-1.14]), the FDA concluded that the improvement in the ITT population was primarily attributed to the results seen in the subgroup of patients with BRCA m. (yahoo.com)
The PROpel results showed the LYNPARZA combination demonstrated a notable clinically meaningful benefit that should rapidly be considered as the standard of care treatment for patients with BRCA m mCRPC. (yahoo.com)
Dave Fredrickson, executive vice president, oncology business unit, AstraZeneca, said, 'There is a critical unmet need for new first-line treatment options for patients with BRCA m mCRPC, and this approval underscores the importance of BRCA testing at metastatic diagnosis. (yahoo.com)
Earle Burgess, MD, an associate professor of medicine at Levine Cancer Institute, Atrium Health, discusses the FDA accelerated approval of rucaparib (Rubraca) in BRCA -positive metastatic castration-resistant prostate cancer (mCRPC). (onclive.com)
In May 2020, the FDA granted an accelerated approval to rucaparib for the treatment of adult patients with germline or somatic BRCA -mutant mCRPC who have received prior androgen receptor-directed therapy and taxane-based chemotherapy. (onclive.com)
This niraparib-based regimen is a welcomed targeted treatment option and, if approved, has the potential to impact the standard of care for men with mCRPC BRCA who are treated with first-line therapy. (outsourcing-pharma.com)
The European Medicines Agency (EMA) has begun a review of rucaparib (Rubraca), a drug used in the treatment of patients with relapsed ovarian and related cancers that have a BRCA mutation. (medscape.com)
The EMA has recommended that, while the review is taking place, clinicians not initiate treatment with rucaparib in new patients with cancer of the ovary , fallopian tubes, or peritoneum that have a BRCA mutation and whose cancer has recurred following at least two platinum-based chemotherapies and who cannot receive further platinum-based therapy (third-line treatment). (medscape.com)
In the EU and the UK, the indication is monotherapy treatment for adult patients with platinum sensitive (relapsed or progressive), BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more prior lines of platinum-based chemotherapy and who are unable to tolerate further platinum-based chemotherapy. (medscape.com)
The ARIEL4 study is comparing rucaparib with chemotherapy in patients with high-grade cancer of the ovary, fallopian tubes, or peritoneum with a BRCA mutation whose cancer has come back after chemotherapy. (medscape.com)
Roughly half of patients with advanced ovarian cancer have homologous recombination deficiency (HRD)-positive tumors, including those with a BRCA mutation, and one in four women have a BRCA mutation. (merck.com)
The Food and Drug Administration (FDA) has approved Lynparza ® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adults with deleterious or suspected deleterious BRCA -mutated metastatic castration-resistant prostate cancer (mCRPC). (empr.com)
Lynparza plus abiraterone approved in the US for the treatment of BRCA -mutated metastatic castration-resistant prostate cancer. (empr.com)
RARITAN, N.J., February 28, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet (DAT), plus prednisone, for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer (mCRPC). (medworm.com)
These data emphasise that the BRCA genes, in particular BRCA2, are key prognostic biomarkers in mCRPC. (cdc.gov)

Alterations in homologous recombination repair (HRR) genes, including BRCA1/2 , found in approximately one-quarter of patients with advanced prostate cancer, can sensitise patients to treatment with PARP inhibitors. (esmo.org)
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® (enzalutamide) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. (pfizer.com)
Notably, the approval of rucaparib is more restrictive in terms of eligibility compared with the FDA approval of olaparib (Lynparza), which is indicated for patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated mCRPC who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate (Zytiga), Burgess says. (onclive.com)
The positive CHMP opinion is based on results of the randomised, double-blind, placebo controlled which assessed whether the addition of Niraparib to AAP improved outcomes in those with first line mCRPC, with or without alterations in homologous recombination repair (HRR) associated genes. (outsourcing-pharma.com)

NEW YORK, November 13, 2023 - Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. (pfizer.com)
2023. Available from https://www.eea.europa.eu/en/topics/at-a-glance/health [Accessed August 2023]. (pmlive.com)
NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) - Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced promising interim data from the Company's Phase 1/2 dose escalation and expansion trial of ARV-766 in men with metastatic castration-resistant prostate cancer (mCRPC). (nlvpartners.com)

This is the largest cohort of BRCA1/2-positive patients with mCRPC. (outsourcing-pharma.com)
We found no association between alterations in PI3K pathway genes or alterations in the DNA damage repair genes BRCA2, BRCA1, and ATM with overall survival and time on treatment with an ARSI," the authors commented. (genengnews.com)

Patients were randomly assigned 1:1 to receive either olaparib 300mg orally twice daily or placebo, in addition to abiraterone and prednisone or prednisolone. (empr.com)

Since the pioneering use of 131 I in differentiated thyroid cancer in the 1940s, remarkable achievements in nuclear medicine endoradiotherapy have been demonstrated, mainly in the treatment of neuroendocrine neoplasms by using 177 Lu-labeled somatostatin analogs or in the treatment of advanced prostate cancer using prostate-specific membrane antigen-directed radionuclide therapy. (snmjournals.org)
In parallel, 68 Ga-labeled somatostatin analogs were approved for imaging of NETs and patient selection for peptide receptor radionuclide therapy (PRRT) ( 6 , 7 ). (snmjournals.org)
VIOLET is a phase I/II trial that will test a new PSMA-targeted radionuclide therapy, 161-Terbium-PSMA-I&T, in patients with progressive mCRPC. (pcf.org)
This treatment is similar in concept to the recently approved radionuclide therapy 177-Lutetium-PSMA-617 (Pluvicto®), but uses 161-Terbium instead of 177-Lutetium as the radioactive-emitting isotope. (pcf.org)
The statement also reviews current clinical struggles physicians face during treatment with 177 Lu-PSMA-617 radionuclide therapy. (appliedradiology.com)
To develop the patient selection criteria and determine appropriate use scenarios, SNMMI assembled an autonomous workgroup to represent a multidisciplinary panel of health care providers with substantive knowledge in the use of nuclear medicine in 177 Lu-PSMA-617 radionuclide therapy. (appliedradiology.com)
We look forward to the potential use of PSMA radionuclide therapy in pre-chemotherapy mCRPC or other settings pending the full results of ongoing trials," noted the authors. (appliedradiology.com)
A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine cancer. (news-medical.net)

The results, published today in Science Translational Medicine , suggest that certain patients with mCRPC may benefit from immune checkpoint inhibitors and provide biomarkers for identifying this subgroup. (mdanderson.org)
However, small groups of mCRPC patients within larger Phase III trials have seen favorable outcomes to checkpoint inhibitors, explained Subudhi, which drove the researchers to ask whether effective immune responses could be stimulated by checkpoint blockade in tumors with low mutation levels. (mdanderson.org)
Immune checkpoint inhibitors (ICIs) are widely sought after for the treatment of different types of cancers. (news-medical.net)
A protein expressed on circulating tumor cells could indicate whether the patient with mCRPC will respond to ARS inhibitors. (medscape.com)

Joseph Wood, a patient, and Deborah Wood, Joseph's wife and caregiver, talk about Joseph's prostate cancer diagnosis and Deborah explains her role as a caregiver. (curetoday.com)
In a proportion of prostate cancer patients, there is evidence of metastatic disease at diagnosis or the disease recurs as distant metastasis despite standard curative treatment. (thieme-connect.com)
An Indian hospital-based study reported that ~70% of prostate cancer patients had metastasis at diagnosis. (thieme-connect.com)
Median baseline PSA levels at mCRPC diagnosis have declined steadily since the approval of PROVENGE in 2010," said Bruce A. Brown, M.D., chief medical officer at Dendreon. (gabio.org)
Besides radiopharmaceuticals that address metabolic processes, approaches focusing on disease-specific targets ( 1 , 2 ) are increasingly important for cancer diagnosis and treatment with radiopharmaceuticals. (snmjournals.org)
Prostate cancer patients with locoregional lymph node disease at diagnosis (N1M0) still have a limited prognosis despite the improvements provided by aggressive curative intent multimodal locoregional external beam radiation therapy (EBRT) with systemic androgen deprivation therapy (ADT). (biomedcentral.com)
This year's meeting has gathered 1,394 participants from 65 countries, and after seven years of holding this congress we have always focused on the central aim to foster education and knowledge in urological cancer and improve diagnosis and treatment through a multi-disciplinary approach," said EAU Sec. General Per Anders Abrahamsson (SE) in the opening of the 6th European Multidisciplinary Meeting on Urological Cancers (EMUC). (uroweb.org)
The synthesis and applications of the peptides are gaining increasing popularity as a result of the developments in biotechnology and bioengineering areas and for a number of research purposes including cancer diagnosis and treatment, antibiotic drug development, epitope mapping, production of antibodies, and vaccine design. (intechopen.com)
Patients with a histological diagnosis of prostate cancer, who are in one of the clinical stages listed in the inclusion criteria. (who.int)
Continuous advances have provided a new understanding of the diagnosis, staging, and treatment of metastatic and advanced prostate cancer. (medscape.com)
Accumulating evidence is showing that, owing to early diagnosis and treatment, the mortality rate associated with prostate cancer has declined since the 1970s. (medscape.com)

Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. (aihta.at)
Cabazitaxel is indicated in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer following docetaxel-based treatment. (wikipedia.org)
In patients with metastatic castration-resistant prostate cancer (mCRPC), overall survival (OS) is markedly enhanced with cabazitaxel versus mitoxantrone after prior docetaxel treatment. (wikipedia.org)
FIRSTANA (ClinicalTrials.gov identifier: NCT01308567) assessed whether cabazitaxel 20 mg/m2 (C20) or 25 mg/m2 (C25) is superior to docetaxel 75 mg/m2 (D75) in terms of OS in patients with chemotherapy-naïve mCRPC. (wikipedia.org)
Randomisation was stratified by HRR gene alteration status (deficient versus non-deficient or unknown) and previous treatment with life-prolonging therapy (docetaxel or abiraterone, or both: yes versus no) in the castration-sensitive setting. (esmo.org)
Treatment with docetaxel in combination with prednisone is the standard first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). (urotoday.com)
For patients failing first-line docetaxel no standard has emerged. (urotoday.com)
The outcome in routine daily clinical practice of a cohort of unselected chemotherapy-naïve mCRPC patients treated with docetaxel plus methylprednisolone as first- and further-line treatment in a single institution was investigated. (urotoday.com)
Out of 41 patients, 28 and 13 received first-line docetaxel according to the D3 and the D1 schedules respectively. (urotoday.com)
The TOT and TFI from the start of second-line treatment, was significantly superior in docetaxel compared to non-docetaxel treated patients. (urotoday.com)
Treatment with docetaxel was well-tolerated and only two patients were withdrawn for non-haematological toxicity during first- and further-line treatment. (urotoday.com)
The results of the retrospective analysis of non-selected patients with mCRPC treated with docetaxel chemotherapy are in line with the data from TAX 327. (urotoday.com)
Normalisation of PSA during first-line treatment with docetaxel is associated with a better survival irrespective of second- or further-line treatment used. (urotoday.com)
Retreatment with docetaxel in second- or further-line remains a treatment option in docetaxel-sensitive patients. (urotoday.com)

The results from the primary analysis of the all-comers population in the phase III TALAPRO-2 study support the consideration of the novel combination of talazoparib plus enzalutamide versus a standard of care, enzalutamide, as a first-line treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC). (esmo.org)
Patients were prospectively assessed for HRR gene alterations in tumour tissue and randomly assigned (1:1) to talazoparib 0.5 mg or placebo, plus enzalutamide 160 mg, administered orally once daily. (esmo.org)
The sponsor, patients, and investigators were masked to talazoparib or placebo, while enzalutamide was open-label. (esmo.org)
Since enzalutamide is innovated and approved by US FDA as a new treatment option for mCRPC patients, drug resistance for enzalutamide is a critical issue during clinical usage. (nih.gov)
In addition, treatment with EnzaR-EVs induces the abilities of cancer stemness, lipid metabolism and enzalutamide resistance in its parental cells. (nih.gov)
They integrated data from whole exome sequencing, gene expression, and histopathological analyses, in combination with patient survival, and duration of treatment with the androgen receptor (AR) signaling inhibitor (ARSI) drugs enzalutamide and abiraterone acetate. (genengnews.com)
All of those patients had to fail abiraterone or enzalutamide. (onclive.com)
Lynparza , a poly (ADP-ribose) polymerase (PARP) inhibitor, is also approved for the treatment of adults with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC who have progressed following prior treatment with enzalutamide or abiraterone. (empr.com)

Metastatic castration-resistant prostate cancer (mCRPC) is a malignant and lethal disease caused by relapse after androgen-deprivation (ADT) therapy. (nih.gov)
Based on this assumption, more and more N1M0 patients are now offered high-dose locoregional external beam radiation therapy (EBRT) with a boost to all visible tumour lesions in the pelvic area combined with 2-3 years concurrent and adjuvant androgen deprivation therapy (ADT). (biomedcentral.com)
Remembering of course that we are going to try to intensify for all patients with metastatic hormone-sensitive disease, our patients are going to have been exposed to more than just ADT [androgen deprivation therapy] alone by the time they hit first-line mCRPC status, for most patients. (medpagetoday.com)
In the first plenary session, Abrahamsson and Maha Hussein (USA) took opposing views on the issue of intermittent androgen deprivation (IAD) and continuous androgen deprivation (CAD) in the treatment of castration-resistant prostate cancer (CRPC). (uroweb.org)
When considering options for androgen deprivation therapy in prostate cancer, GnRH antagonists may be better choices than agonists for patients with cardiovascular risk, says Dr Gerald Chodak. (medscape.com)

To try and identify the most important prognostic markers in mCRPC, the investigators undertook a complete and comprehensive analysis of genetic, molecular, cellular, and clinical outcomes data from 444 tumor samples, taken from 429 patients. (genengnews.com)
Our objective was to evaluate the prognostic value of end-of-treatment prostate-specific membrane antigen (PSMA) PET/CT (PSMA-PET) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA radioligand therapy (PSMA-RLT). (bvsalud.org)

Other end points included time to prostate-specific antigen (PSA) progression, objective response rate (ORR), time to second disease progression (PFS2), time to pain progression, and patient-reported outcomes. (urologytimes.com)
Patient-reported outcomes showed a superior experience regarding post-procedure BPH symptoms with the UroLift prostatic urethral lift over Rezum tissue ablation with steam injection. (urologytimes.com)
In particular, we look forward to presenting new data for ERLEADA ® and niraparib, which reinforce our continued commitment to improve outcomes for patients diagnosed with prostate cancer across the disease spectrum. (jnj.com)
New nomograms can predict survival outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177 prostate-specific membrane antigen ( 177- Lu-PSMA), according to a study published in The Lancet Oncology . (renalandurologynews.com)
The researchers used the OS nomogram to stratify patients into low- and high-risk groups, and OS outcomes were consistently superior in the low-risk groups. (renalandurologynews.com)
As with OS, PSA-PFS outcomes were superior in low-risk patients. (renalandurologynews.com)
Our nomograms for outcomes after ¹⁷⁷Lu-PSMA in late-stage mCRPC could help in trial design and provide guidance for clinicians," the researchers wrote. (renalandurologynews.com)
By monitoring early-response biomarkers in men undergoing 177Lu-PSMA prostate cancer treatment, physicians can personalize dosing intervals, significantly improving patient outcomes. (news-medical.net)
Understanding how these genomic events impact prognosis and/or treatment response is vital for optimising clinical outcomes. (cdc.gov)

Across all patients, median progression-free survival (PFS) according to radiographic imaging was 3 months, and median overall survival (OS) was 24.3 months. (mdanderson.org)
Findings from the phase 3 MAGNITUDE trial showed that adding the PARP inhibitor niraparib (Zejula) to the antiandrogen agent abiraterone acetate (Zytiga) significantly extended radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. (urologytimes.com)
The statistical analysis included a prespecified futility analysis in the biomarker-negative population after approximately 200 patients were enrolled and approximately 125 compositive events of either radiographic or PSA progression or death had occurred. (urologytimes.com)
This approval was based on an exploratory subgroup analysis of the Phase 3 PROpel trial which showed that LYNPARZA plus abi/pred demonstrated clinically meaningful improvements in both radiographic progression-free survival (rPFS) (HR=0.24 [95% CI, 0.12-0.45]) and overall survival (OS) (HR=0.30 [95% CI, 0.15-0.59]) versus abi/pred alone in patients with BRCA m mCRPC. (yahoo.com)
Andrew Armstrong, MD, ScM, Duke Cancer Institute, Durham, N.C. and an investigator in the trial, said, 'Preventing or delaying radiographic progression is an important clinical endpoint in assessing cancer treatment and is very important to patients, their caregivers and their families. (yahoo.com)
Small molecule drug, Niraparib combined with abiraterone acetate (AA) and prednisone (P) significantly reduces the risk of disease progression, or death, in patients with a type of prostate cancer, a consultant in Spain has said. (outsourcing-pharma.com)
We've seen that in these patients, niraparib combined with abiraterone acetate and prednisone significantly reduces the risk of disease progression or death compared to AAP. (outsourcing-pharma.com)
Phase 3 data showed that the addition of the AKT inhibitor ipatasertib to standard therapy boosted radiographic progression-free survival in patients with advanced castration-resistant prostate cancer whose tumors had PTEN loss. (urologytimes.com)
However, patients who were randomly assigned to receive chemotherapy were permitted to cross over if disease progression occurred and receive rucaparib, the company pointed out. (medscape.com)
LYNPARZA plus bevacizumab also improved median progression-free survival (PFS) to nearly four years (46.8 months) versus 17.6 months with bevacizumab plus placebo, and 46.1% of patients who received LYNPARZA in combination with bevacizumab remain progression free versus 19.2% of patients who received bevacizumab alone. (merck.com)
In terms of patient selection, workgroup members agreed that PSMA PET should be performed within three months of treatment or since progression on the last therapy to ensure that the current disease state is represented. (appliedradiology.com)
The goal of the study is to determine if vaccine administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients. (dana-farber.org)

However, C20 and C25 did not demonstrate superiority for OS versus D75 in patients with chemotherapy-naïve mCRPC. (wikipedia.org)
This recommendation, however, does not affect the use of rucaparib as maintenance treatment following chemotherapy, the agency noted. (medscape.com)
An interim analysis favored the chemotherapy treatment arm vs the rucaparib arm, the company said. (medscape.com)
The Phase 3 PAOLA-1 trial evaluated LYNPARZA in combination with bevacizumab as first-line maintenance therapy in patients with advanced ovarian cancer, who were without evidence of disease after surgery or following response to platinum-based chemotherapy. (merck.com)
Treatment of mCRPC after chemotherapy and ARPI was considered appropriate, while treatment of mCRPC after ARPI and before chemotherapy was considered rarely appropriate. (appliedradiology.com)
For patients who have visceral crisis, cord compression, something that is really dramatically an event that's rapidly progressive, chemotherapy is still probably the best approach. (medpagetoday.com)
NCT03732820 ), which included 796 adults with mCRPC who had not received prior chemotherapy or new hormonal agents in the mCRPC setting. (empr.com)
Patients with hormone-sensitive metastatic prostate cancer (HSPC), who have not received previous superantiandrogens or chemotherapy. (who.int)

Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer (mCRPC). (curetoday.com)
Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should know before, during and after the scan. (curetoday.com)
An overview of metastatic castration-resistant prostate cancer (mCRPC) and the role of PSMA in mCRPC. (curetoday.com)
PURPOSE: To review the current literature and discuss potential future roles of the novel positron emission tomography (PET) tracers targeting the prostate-specific membrane antigen (PSMA) in patients with castration-resistant prostate cancer (CRPC). (uzh.ch)
Additionally, illustrative cases of CRPC patients from our own institution who were restaged and treated based on PSMA-PET scan results are provided. (uzh.ch)
Currently, no clear consensus exists regarding treatment response assessment in PSMA-PET scans for mCRPC patients undergoing treatment. (uzh.ch)
PSMA-guided metastasis-directed radiotherapy may not only alleviate local symptoms but has the potential to defer systemic treatment in patients with oligoprogressive CRPC. (uzh.ch)
Until future studies define the role of PSMA-PET in patients with CRPC, the current standard for imaging remains bone scan and computerized tomography. (uzh.ch)
On the basis of the high and consistent expression of prostate-specific membrane antigen (PSMA) in metastatic prostate cancer (PC), the goal of this study was the development, preclinical evaluation, and first proof-of-concept investigation of a PSMA inhibitor for imaging and therapy (PSMA I&T) for 68 Ga-based PET and 177 Lu-based endoradiotherapeutic treatment in patients with metastatic and castration-resistant disease. (snmjournals.org)
Initial human PET imaging studies using 68 Ga-PSMA I&T, as well as endoradiotherapeutic treatment of 2 patients with metastatic PC using 177 Lu-PSMA I&T, were performed. (snmjournals.org)
Endoradiotherapy with 177 Lu-PSMA I&T in 2 patients was found to be effective and safe with no detectable side effects. (snmjournals.org)
68 Ga-PSMA I&T shows potential for high-contrast PET imaging of metastatic PC, whereas its 177 Lu-labeled counterpart exhibits suitable targeting and retention characteristics for successful endoradiotherapeutic treatment. (snmjournals.org)
PSMA expression correlates with the malignancy of the disease, being further increased in metastatic and hormone-refractory patients ( 4 ). (snmjournals.org)
This study aims to explore the combination of standard EBRT and ADT complemented with a single administration of [ 177 Lu]Lu-PSMA-617 in curative intent treatment for N1M0 prostate cancer. (biomedcentral.com)
The PROQURE-I study is a multicenter prospective phase I study investigating standard of care treatment (7 weeks EBRT and 3 years ADT) complemented with one concurrent cycle (three, six, or nine GBq) of systemic [ 177 Lu]Lu-PSMA-617 administered in week two of EBRT. (biomedcentral.com)
A maximum of 18 patients with PSMA-positive N1M0 prostate cancer will be included. (biomedcentral.com)
This is the first prospective study to combine EBRT and ADT with [ 177 Lu]Lu-PSMA-617 in treatment naïve men with N1M0 prostate cancer, and thereby explores the novel application of [ 177 Lu]Lu-PSMA-617 in curative intent treatment. (biomedcentral.com)
Either 18 F-DCFPyL or 68 Ga-PSMA-11 can be used for PSMA PET imaging, and 18 F-FDG PET is not required as a standard patient selection tool. (appliedradiology.com)
In addition, patients should be imaged with either contrast-enhanced CT or MRI to identify potential PSMA-negative disease. (appliedradiology.com)
With the approval of 177 Lu-PSMA-617, a new class of therapeutics is available to patients with prostate cancer. (appliedradiology.com)
There were 270 eligible patients who had received 177- Lu-PSMA once every 6 to 8 weeks for a maximum of 4 to 6 cycles. (renalandurologynews.com)
In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. (news-medical.net)
METHODS: Prospectively enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) initiating ARSi underwent serial PSA measurements and WB-PSMA PET at baseline, 1-week, and 3-months post-ARSi. (bvsalud.org)
Nine/9 patients completed PSMA PET at 1-week, 5/9 at 3-months. (bvsalud.org)
CONCLUSIONS: Our prospective trial involving 9 mCRPC patients initiating ARSi did not show significant modulation of PSMA expression measured on WB-PSMA PET at 1-week. (bvsalud.org)
METHODS: Patients who underwent at least 2 68Ga-PSMA-11 PET/CT scans between October 2016 and April 2021 (n = 372) and started a new line of ADT ± ARSi between PET1 and PET2 were retrospectively screened for inclusion. (bvsalud.org)
mCRPC patients who underwent PSMA-RLT with available baseline PSMA-PET (bPET) and end-of-treatment PSMA-PET (ePET) within 6 mo of the last PSMA-RLT cycle were eligible. (bvsalud.org)

The researchers noted a "favorable" cohort of nine patients with PFS greater than six months and OS greater than one year, and an "unfavorable" cohort of ten patients with PFS less than six months and OS less than one year. (mdanderson.org)
Based on prescreening results, patients were allocated into the biomarker-positive cohort or the biomarker-negative cohort, which had a planned enrollment of 400 and 600 patients, respectively. (urologytimes.com)
The researchers divided these patients into a development cohort (n=196) and 2 validation cohorts (n=74). (renalandurologynews.com)

As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. (mdanderson.org)
Optimising treatment and management strategies in prostate cancer took up the first plenary session of the 6th European Multidisciplinary Meeting on Urological Cancers (EMUC) in Lisbon, Portugal, with experts discussing prospects in imaging, radiotherapy and benefits of medical treatment. (uroweb.org)
The clinician should then discuss of the risks and benefits of a baseline PSA test with the patient, and consider a baseline DRE to identify high-risk cancers associated with a seemingly normal PSA. (medscape.com)

The phase III PROfound study with olaparib and TRITON3 with rucaparib also showed benefit using a PARP inhibitor as monotherapy for patients with pretreated mCRPC who had HRR alterations, with prolonged PFS versus control treatment. (esmo.org)
At the seven-year descriptive OS analysis, 67% of LYNPARZA patients were alive versus 47% of placebo patients (44% of whom had a subsequent PARP inhibitor), and 45% of LYNPARZA patients versus 21% of placebo patients were alive and had not received a first subsequent treatment. (merck.com)
I disagree a bit, Tanya, on the fact that I never considered shifting from one androgen signal inhibitor to the other as a valid option for our patients. (onclive.com)

monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). (stockhouse.com)
In the phase II TALAPRO-1 study, talazoparib monotherapy (1 mg/day) showed durable antitumour activity and a manageable safety profile in patients with heavily pretreated mCRPC with HRR deficiency. (esmo.org)

Current research in theranostics is addressing new targets but-equally important-the optimization of radiopharmaceutical doses and dose schedules, investigation of combination therapies, and treatment at earlier tumor stages. (snmjournals.org)
Pembrolizumab has been granted a second tumor-agnostic FDA indication, this one for patients with solid tumors with a high tumor mutational burden. (urologytimes.com)
If successful, this project will improve understanding of tumor visibility by Micro-Ultrasound, and result in a 3-minute prostate scan and urine sample test that identifies patients at risk for prostate cancer and improves decisions on whether patients should undergo prostate biopsy or not. (pcf.org)
Our study really got under the bonnet of prostate cancer to understand the 'engine' driving tumor growth and explore how a wide range of genes affect the disease and its response to treatment," stated study co-author Johann de Bono, MD, PhD, Regius professor of cancer research at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust. (genengnews.com)
A total of 5922 H&E sections representing 7473 biopsy cores from 423 patient cases (digitized using three scanners) were assessed concerning tumor detection. (cdc.gov)

Despite the improvements provided by aggressive multimodal locoregional EBRT with systemic long-term ADT, patients with N1M0 disease still have a suboptimal prognosis. (biomedcentral.com)

Belinostat is under clinical development by Acrotech Biopharma and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). (pharmaceutical-technology.com)
According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. (pharmaceutical-technology.com)
In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone. (wikipedia.org)
Joseph Wood details his treatment journey with metastatic castration-resistant prostate cancer (mCRPC) and how the journey has impacted his wife and caregiver, Deborah Wood. (curetoday.com)
Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC). (curetoday.com)
Dr Matthew Rettig reviews the front-line treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) and what factors are considered when choosing appropriate treatment. (curetoday.com)
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy , a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a Phase II trial at The University of Texas MD Anderson Cancer Center . (mdanderson.org)
There is a need for improved therapeutic approaches for patients with advanced metastatic castration-resistant prostate cancer (mCRPC), whilst on the other extreme, there is a need to accurately identify clinically significant prostate cancer in individuals presenting with elevated PSA levels or inconclusive MRI results. (pcf.org)
First-line options for treating metastatic castration-resistant prostate cancer (mCRPC) were debated throughout the annual meeting of the American Urological Association (AUA). (medpagetoday.com)
Genomic alterations in DNA damage response (DDR) genes are common in metastatic castration-resistant prostate cancer (mCRPC). (cdc.gov)
Patients with metastatic castration-resistant prostate cancer (mCRPC), who have not received previous a.2. (who.int)

Median follow-up after the first treatment was 45.5 months. (mdanderson.org)
The median survival of four years following treatment with PROVENGE is meaningful," said Celestia S. Higano, M.D., FACP, lead author of the PROCEED analysis, and professor, Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center. (gabio.org)
Among patients with a baseline PSA ≤22.1 ng/mL, the median OS was 41.3 months (3.4 years) for those treated with sipuleucel-T vs. 28.3 months for those in the control arm - an improvement of 13 months. (gabio.org)
Patients were followed for a median of 46.6 months. (gabio.org)
The median rPFS and median OS were not reached for patients in the olaparib arm compared with a median of 8 months and 23 months, respectively, for the placebo arm. (empr.com)
Patients had a median of 4 prior lines of therapy in the Phase 1 trial and 5 prior lines of therapy in the Phase 2 trial. (nlvpartners.com)

The working group also agreed that treatment of patients with metastatic castration-sensitive prostate cancer was rarely appropriate. (appliedradiology.com)

In patients considering clinical trial enrollment, the risks and potential benefits of experimental treatment modalities must be clearly outlined. (medscape.com)
Robust and accurate risk assessment might aid physician decision-making regarding treatment plans and clinical trial patient stratification. (renalandurologynews.com)
This clinical trial, Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE), was led at UCLA and included 154 analyzable patients with prostate cancer who were randomised to either a CT-guidance arm (76 patients) or an MRI-guidance arm (78 patients). (ecancer.org)
A clinical trial is being conducted to see the benefit of a known lipid-lowering drug such as pitavastatin in patients with advanced prostate cancer who are being treated with the new anti-androgens. (who.int)

Joseph Wood and his wife and caregiver, Deborah, share their concerns and questions about radioligand therapy and how the COVID-19 pandemic has impacted their treatment experience. (curetoday.com)
Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. (yahoo.com)
Many patients with mCRPC are only able to receive one line of therapy, as the disease can progress quickly. (yahoo.com)
The success of adaptive therapy (AT), whereby treatment is cycled on and off using patient-specific treatment triggers, is hypothesized to be due to the competitive suppression of the resistant population by the sensitive population. (mdpi.com)
There may exist a subset of patients who might benefit from slight modifications to AT, whereby treatment is initially delayed and subsequently cycled to remain between predetermined, patient-specific bounds, i.e., range-bounded adaptive therapy (RBAT). (mdpi.com)
Of those, 95% were treated with PROVENGE as first-line therapy for mCRPC as recommended by the National Comprehensive Cancer Network (NCCN). (gabio.org)
Learn about salvage radiation therapy (SRT) as a type of cancer treatment given to men who had their prostate removed yet their prostate-specific antigen (PSA) levels begin to rise. (urologyhealth.org)
Because of that, it's really critical to recognize what a patient has had before and try to switch mechanism of action, particularly if that patient has had intensified therapy with an AR [androgen receptor]-targeted agent. (medpagetoday.com)
Importantly, we find that RB1 loss is the only genomic factor that is significantly associated with both survival and time on ARSI therapy in mCRPC," the investigators wrote. (genengnews.com)
Trial Description: This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. (dana-farber.org)
The novel treatment, SnyKIR-110, is a T-cell therapy designed to treat patients with mesothelioma, cholangiocarcinoma (bile duct cancer) and ovarian cancer. (medworm.com)
The patients in this trial received extensive prior therapy for mCRPC and had limited alternative treatment options," said Ron Peck, M.D., chief medical officer at Arvinas. (nlvpartners.com)
For treatment recommendations for patients with a life expectancy ≥20 y, see initial therapy for Low Risk of Recurrence, below. (medscape.com)

In both the Phase 1 dose escalation and Phase 2 dose expansion, 100% of patients were previously treated with at least one or more novel hormonal agents. (nlvpartners.com)

Between 7 January 2019 and 17 September 2020, 805 patients were enrolled and randomly assigned, 402 to the talazoparib group and 403 to the placebo group. (esmo.org)

Patients were randomized 1:1 to receive 200 mg of niraparib once daily plus abiraterone or placebo plus abiraterone in each of the cohorts. (urologytimes.com)
As such, only a total of 423 patients with HRR gene alterations were subsequently randomized to niraparib plus abiraterone (n = 212) or placebo plus abiraterone (n = 211). (urologytimes.com)
Based on the results of PROpel trial, olaparib plus abiraterone has been approved the EU and several other countries for the treatment of patients with mCRPC. (pmlive.com)

During their research Janssen found evidence that shows that prostate cancer is the most common cancer in men in Europe and despite treatment advances, for those whose cancer has progressed to mCRPC, the impact can be devastating with an average overall survival ranging from 13-36 months. (outsourcing-pharma.com)

The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. (stockhouse.com)
In the U.S., prostate cancer is the second most common cancer in men, and despite an increase in the number of available therapies for patients with mCRPC, five-year survival remains low. (yahoo.com)
These include the role of androgen receptor-targeted therapies, the role of 223 Ra, treatment-related toxicities, when to consider cessation of treatment, exceptional responders and restarting treatment, and imaging during treatment. (appliedradiology.com)
The Phase 1 dose escalation of ARV-766 was designed to assess its safety, tolerability, and pharmacokinetics (PK) in men with mCRPC who have progressed on standard of care therapies, as well as to identify recommended Phase 2 doses for further dose optimization. (nlvpartners.com)

So if we're changing mechanism of action, how do we choose well for asymptomatic patients, minimally symptomatic patients. (medpagetoday.com)

Dr. Sadar is an expert witness for Astellas, Pfizer, and University of California on patents covering Xtandi®, used for the treatment of prostate cancer in the USA with global sales greater than $3.5 billion per year. (bcgsc.ca)

It is not approved for the treatment of patients with platinum-resistant tumors. (medscape.com)
We identified one particular genetic mutation that seems to indicate that tumors are going to be very aggressive, and that the affected men need the most intensive treatment we have available. (genengnews.com)

Factors such as toxicity profile, cost, and physicians' and patients' preferences are vital in choosing one of these options over the other. (thieme-connect.com)
It is considered likely that this study will confirm tolerability as the combined toxicity of these treatments is expected to be limited. (biomedcentral.com)
In this trial, we demonstrated that the reduction in treatment volumes facilitated by MRI guidance leads to a significant reduction in moderate physician-scored toxicity and to a reduction in the proportion of patients noting significant decrements in patient-reported outcome metrics in the near term," said Dr. Kishan. (ecancer.org)

Notably, the addition of an antiandrogen agent like abiraterone has been theorized to augment responses in all-comers, serving as the rationale for the randomized, double-blind MAGNITUDE trial, which evaluated the value of adding niraparib to abiraterone in patients with mCRPC with and without HRR gene alterations. (urologytimes.com)
Patients with HRR gene alterations were randomised to receive niraparib 200 mg once daily plus AAP or placebo and AAP. (outsourcing-pharma.com)
At Janssen, we are dedicated to continued innovation in prostate cancer and now look forward to working with health authorities to bring this niraparib-based treatment option to patients as soon as possible. (outsourcing-pharma.com)

In the past, prostate cancer patients with nodal metastases were not considered for curative treatment, based on the assumption that cure was neither feasible nor beneficial, based on the hypothesis that patients with lymph node metastases are affected by a systemic disease. (biomedcentral.com)
These developments are leading to higher confidence that at least some of the current prostate cancer patients staged N1M0 may not yet have systemic disease, and therefore may potentially benefit from an aggressive multimodal treatment approach. (biomedcentral.com)
The research results, reported in the Proceedings of the National Academy of Sciences ( PNAS ), also suggest that some prostate cancer patients may respond to treatment using an existing breast cancer drug combined with immunotherapy. (genengnews.com)
Disturbing Pattern of Recurrence in Men Post Radical Prostatectomy Dr Gerald Chodak discusses the clinical implications of new data on recurrence patterns in prostate cancer patients following radical prostatectomy. (medscape.com)
Dr Chodak explores several unanswered questions posed by a multicenter analysis comparing treatments in more than 1000 advanced prostate cancer patients. (medscape.com)
Prostate Cancer Mortality in Men With a Negative Initial Biopsy Dr Chodak discusses the next steps for prostate cancer patients following a negative initial biopsy, based on 20 years of data analyzed in a recent population-based study of prostate cancer mortality risk. (medscape.com)

Anti-PD-1/PD-L1 agents were associated with similar efficacy across pure and variant histologies in patients with advanced urothelial carcinoma, with the exception of those with a neuroendocrine variant. (urologytimes.com)
Increased efficacy is considered likely since both individual treatments have proven high anti-tumour effect as mono-treatments. (biomedcentral.com)
Trial Description: This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax ( Prostate -specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with localized prostate cancer . (dana-farber.org)

As many as 30% of patients with mCRPC will harbor alterations in genes associated with HRR. (urologytimes.com)

In an exploratory subgroup analysis of HRD-positive patients, LYNPARZA plus bevacizumab provided a clinically meaningful improvement in OS, reducing the risk of death by 38% (HR=0.62 [95% CI, 0.45-0.85]) versus bevacizumab alone. (merck.com)
65.5% of patients who received LYNPARZA plus bevacizumab were still alive at five years versus 48.4% who received bevacizumab alone. (merck.com)

Patients interested in IAD should be counseled regarding potential negative impact on survival and modest impact on QoL," she said. (uroweb.org)

The American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology have released a joint guideline for advanced prostate cancer to address the growing treatment options and complexity of the paradigm. (urologytimes.com)
Clovis Oncology, the manufactuer, told Medscape Medical News that "almost all rucaparib use is in the maintenance treatment setting," which is not the subject of this review. (medscape.com)

The novel oral penem anti-infective compound sulopenem showed stronger clinical activity than ciprofloxacin in patients with uncomplicated urinary tract infections with quinolone resistant pathogens, according to findings from the phase 3 SURE1 trial. (urologytimes.com)
This model will use data including age, PSA, DRE findings, prostate volume, and whole gland Micro-Ultrasound images to risk stratify patients following PSA screening. (pcf.org)
The AR findings indicate that targeting androgen receptor signaling using current ARSI approaches may not be complete, and that "further targeting of the protein may be clinically beneficial in patients who develop resistance to these agents. (genengnews.com)

citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. (wikipedia.org)
Joseph Wood and his caregiver, Deborah Wood, provide advice for patients and caregivers with prostate cancer who may be in similar situations, and comment on the support they have received from their family and community. (curetoday.com)
In TALAPRO-2 patients were enrolled from 223 hospitals, cancer centres, and medical centres in 26 countries in North America, Europe, Israel, South America, South Africa, and the Asia-Pacific region. (esmo.org)
Your gift will help support our mission to end cancer and make a difference in the lives of our patients. (mdanderson.org)
While advanced prostate cancer was historically defined as distant metastatic disease, the current definition includes disease stages that range from recurrence of prostate-specific antigen (PSA) elevation after failure of local treatment to widespread metastasis. (medscape.com)
Although cure of metastatic prostate cancer remains elusive, continuous advances in management have improved the outlook in these patients. (medscape.com)
For patient education information, see Prostate Cancer . (medscape.com)
NEW YORK--Pharmaceutical companies are currently investigating 25 new treatments for prostate cancer, including a potential vaccine, Alan Holmer, president of the Pharmaceutical Research and Manufacturers of America, said at a media briefing conducted by the American Cancer Society and the New York City-based Cancer Research Institute. (cancernetwork.com)
NEW YORK--Pharmaceutical companies are currently investigating25 new treatments for prostate cancer, including a potential vaccine,Alan Holmer, president of the Pharmaceutical Research and Manufacturersof America, said at a media briefing conducted by the AmericanCancer Society and the New York City-based Cancer Research Institute. (cancernetwork.com)
Another new computer technique, the inverse approach to 3D-CRTtreatment planning, which has been used on about a dozen patientsso far at Sloan-Kettering, holds the promise of providing expertconformal radiotherapy planning to hospitals and cancer centersthat could not otherwise provide such treatment, Dr. Fuks said. (cancernetwork.com)
Without treatment, about 20% of DCIS cases will lead to invasive breast cancer within 10 years. (drugs.com)
LCIS doesn't require treatment, but it does increase a woman's risk of developing cancer in other areas of both breasts. (drugs.com)
5.27 ng/mL did not receive any additional cancer treatments for at least one year. (gabio.org)
PROVENGE is the only FDA-approved immunotherapy made from a patient's own immune cells for the treatment of prostate cancer. (gabio.org)
Get the Prostate Cancer Patient Guide, available as a free emailed pdf. (pcf.org)
Current prostate cancer screening methods either lack specificity (PSA tests) or are costly and not widely available (MRI), thus many more patients undergo invasive prostate biopsies than are necessary. (pcf.org)
Guide with information about how to diagnose, treat and manage bladder cancer, including a patient perspective. (urologyhealth.org)
How to diagnose, screen, treat and manage early-stage prostate cancer, including a patient perspective. (urologyhealth.org)
Download this football-themed prostate health resource covering prostatitis, BPH and prostate cancer screening, treatment and life after prostate cancer. (urologyhealth.org)
Download this special issue focusing on bladder cancer that includes information for patients and caregivers on the basics such as the stages of this cancer, symptoms, treatments, risk factors and how to learn more. (urologyhealth.org)
Download this special issue focusing on prostate cancer that includes information for patients and caregivers on risk factors, healthy living tips and more. (urologyhealth.org)
Learn about treatment intensification for Hormone Sensitive Prostate Cancer and questions to ask your doctor. (urologyhealth.org)
Learn about Hormone Sensitive Prostate Cancer, common treatments and what to expect after treatment. (urologyhealth.org)
Learn more about the basics of bladder cancer including types, causes, symptoms, testing and treatment options. (urologyhealth.org)
More than two-thirds of patients with ovarian cancer are diagnosed with advanced disease, and approximately 50-70% of these patients die within five years. (merck.com)
p=0.4118) in patients with newly diagnosed advanced ovarian cancer. (merck.com)
In what they claim is the largest study of its kind to date, an international team of scientists has identified a gene mutation in patients with prostate cancer that increases their risk of death more than threefold, and increase the likelihood of relapse nearly sevenfold. (genengnews.com)
Trial Description: This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer , and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer . (dana-farber.org)
Trial Description: This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. (dana-farber.org)
For men who undergo radiotherapy for localised prostate cancer, the precise targeting capabilities of MRI guidance resulted in fewer toxicities and better quality of life, as judged by patients and the doctors treating them, according to new research from UCLA Jonsson Comprehensive Cancer Center. (ecancer.org)
MRI guidance offers several advantages over standard CT guidance, most notably the ability to dramatically reduce planning margins, providing more focused treatment with less injury to nearby normal tissues and organs," said Amar Kishan, M.D., a radiation oncologist at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center and the study's lead author. (ecancer.org)
Additionally, Lynparza is indicated for the treatment of ovarian cancer , breast cancer , and pancreatic cancer . (empr.com)
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the September issue of The Journal of Nuclear Medicine. (news-medical.net)
Unfortunately, only 20-30% patients with cancer respond to ICI treatment. (news-medical.net)
The US NCCN guidelines recommend that all, or a high proportion of, patients with a personal history of breast, ovarian, endometrial, pancreatic, colorectal, and prostate cancer should undergo germline testing. (cdc.gov)
What Is the Best Treatment for High-Grade Prostate Cancer? (medscape.com)
HIFU-Hemiablation for Treatment of Prostate Cancer? (medscape.com)
Dr Gerald Chodak questions the value of the IDEAL study to evaluate HIFU-hemiablation as the primary treatment for prostate cancer. (medscape.com)
Dr Gerald Chodak suggests that the Wallis study has too many biases to recommend surgery over radiation for localized prostate cancer treatment. (medscape.com)
Patients with hormone-sensitive metastatic prostate cancer (HSPCm), who have not received previous line a.1. (who.int)
For patient education information, see the Men's Health Center and the Cancer Center, as well as Prostate Cancer. (medscape.com)
Breast Cancer Research and Treatment. (lu.se)
Abstract P1-18-10: Preoperative treatment of HER2-positive breast cancer in South Sweden. (lu.se)

Other topics discussed were optimising imaging for biochemical recurrence given by Jelle Barentsz (NL), understanding the natural history of progressing PCa and whether treatment is always needed by Martin Gleave (CA), curative radiotherapy by M. Van Vulpen (NL), curative surgery for local recurrence and patient selection by Steven Joniau (BE), and optimal treatment for mCRPC by G. Attard (GB). (uroweb.org)

Prospective studies on larger cohorts of patients are warranted and planned. (snmjournals.org)
Five external cohorts of patients with multifocal prostate biopsy were analyzed from high-volume pathology institutes. (cdc.gov)

Safety was evaluated in all patients who received at least one dose of study drug. (esmo.org)
MRI technology is more costly than CT, both in terms of upfront equipment expenses and longer treatment times, which is one reason our study set out to determine if MRI-guided technology offers tangible benefits for patients. (ecancer.org)
A unique aspect of the study was its inclusion of outcome measures assessed by patients as well as physicians. (ecancer.org)
Information for patients and study volunteers, including frequently asked questions . (sutterhealth.org)
RESULTS: Due to low enrollment rate, the study was closed before reaching the recruitment goal of 30 patients. (bvsalud.org)

Drs Matthew Rettig and Jeremie Calais explain what it means to be a part of a collaborative team and how communication plays a big role in patients receiving optimal treatment. (curetoday.com)

ESSA has filed an update on clinicaltrials.gov announcing that it has begun recruiting patients for its phase 1/2 combination trial (EPI-7386 and Astellas/Pfizer's Enzalutimide). (stockhouse.com)
The confirmatory phase 3 TRITON3 trial (NCT02975934) is ongoing to further evaluate rucaparib in patients with HRR-deficient mCRPC, concludes Burgess. (onclive.com)

PROpel has demonstrated that HRR m [mutation] testing is not necessary to identify patients who may derive benefit from the combination of olaparib and abiraterone [Lynparza]. (ajmc.com)
Among patients who received LYNPARZA in combination with abi/pred, 16% permanently discontinued treatment with LYNPARZA due to an AR, 48% had a dosage interruption of LYNPARZA and 21% had their dose of LYNPARZA reduced. (yahoo.com)
We look forward to bringing the benefit of this LYNPARZA combination to patients earlier in their treatment. (yahoo.com)

And if a patient has bone-only metastatic disease and has some symptomatology, even if that's just an anemia or some mild fatigue, then radium can be an option there as well. (medpagetoday.com)

Several patients were up-staged from non-metastatic CRPC (nmCRPC) to metastatic CRPC (mCRPC). (uzh.ch)

Overall, at the interim analysis, 88% of all ARIEL4 participants had received rucaparib either as the treatment they were assigned to or as crossover treatment. (medscape.com)
The EMA said in its announcement that it will assess all available information on the use of rucaparib as third-line treatment and recommend whether the product's marketing authorization in the EU should be maintained or changed. (medscape.com)

Diseases3

Chemicals and Drugs6

Analytical, Diagnostic and Therapeutic Techniques and Equipment3

Phenomena and Processes1

Health Care1

Mutations24

Castrate-resistant9

BRCA15

Homologous recombination4

20233

BRCA12

Abiraterone and prednisone1

Radionuclide therapy8

Inhibitors4

Diagnosis11

Docetaxel14

Enzalutamide8

Androgen deprivation5

Prognostic2

Outcomes9

Progression12

Chemotherapy8

PSMA27

Cohort3

Cancers3

Inhibitor3

Monotherapy2

Tumor5

Prognosis1

Resistant prostate cancer11

Median6

Castration-sensitive1

Clinical Trial4

Therapy13

Hormonal agents1

20201

Plus abiraterone3

Overall survival1

Therapies4

Symptomatic1

XTANDI1

Tumors2

Toxicity3

Niraparib3

Prostate cancer patients6

Efficacy3

Genes1

Versus2

Survival1

Oncology2

Findings3

Cancer43

Curative1

Cohorts2

Study5

Optimal treatment1

Phase2

LYNPARZA3

Metastatic disease1

NmCRPC1

Rucaparib2